Key result
Sulphasalazine is linked to drug-induced systemic lupus erythematosus presenting as pleuropericarditis.
Case Report (n=1)
Sulfasalazine can induce a lupus-like syndrome presenting as life-threatening pleuropericarditis in patients with rheumatoid arthritis, requiring immediate discontinuation of the offending drug.
Answers are grounded in this paper and cite their sources.
Supports vigilance for sulfasalazine-induced lupus pleuropericarditis in RA; single case leaves causality and incidence open.
Pericarditis, a life-threatening condition, can be seen in rheumatic diseases. It may occur secondary to rheumatic diseases or drugs used in the treatment. In this article, we present a case of 47-year-old female, who had joint complaints for 15 years and had treatment of methotrexate and corticosteroid for six years. In the last three months, after the addition of sulphasalazine to her treatment, she developed chest pain, palpitations, rash, fever, and pleuropericarditis and was subsequently diagnosed with systemic lupus erythematosus induced by sulfasalazine. When cardiac disease is seen in a patient with rheumatoid arthritis, medication should be discontinued immediately, and it should be kept in mind that cardiac involvement may be associated with drugs.
No takes yet. Share an insight, caveat, or question.
Özcan Hız (2011) conducted a case report in Rheumatoid Arthritis and Drug-Induced Lupus-Like Syndrome (n=1). Sulphasalazine was evaluated on Development of systemic lupus erythematosus induced by sulfasalazine (pleuropericarditis, chest pain, palpitations, rash, fever). Sulphasalazine exposure in a 47-year-old female with rheumatoid arthritis was associated with the development of drug-induced systemic lupus erythematosus presenting as pleuropericarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: